Dr. Teshamae Monteith
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Miami, Lm Miller School of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 104
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: University of Miami, Lm Miller School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
FL license ME110436
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- University of Miami (2,377 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 104
- Services billed
- 15,069
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 14,400 | 29 |
| Established patient office or other outpatient visit, 30-39 minutes | 115 | 87 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 73 | 29 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 21 | 21 |
| Established patient office or other outpatient visit, 20-29 minutes | 15 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Emgality Pen (galcanezumab-gnlm) Other prescribers in Miami, FL | 91 |
| Naproxen Other prescribers in Miami, FL | 27 |
| Ajovy Autoinjector (fremanezumab-vfrm) | 25 |
| Sumatriptan Succinate Other prescribers in Miami, FL | 24 |
| Rizatriptan (rizatriptan benzoate) Other prescribers in Miami, FL | 24 |
| Aimovig Autoinjector (erenumab-aooe) Other prescribers in Miami, FL | 21 |
| Metoclopramide Hcl Other prescribers in Miami, FL | 20 |
| Topiramate Other prescribers in Miami, FL | 20 |
| Naratriptan Hcl | 17 |
| Ketorolac Tromethamine Other prescribers in Miami, FL | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 15 payments worth $12,521 in total to this clinician.
| Pfizer Inc. | $5,033 |
|---|---|
| Lundbeck LLC | $4,421 |
| Amneal Pharmaceuticals LLC | $3,000 |
| AbbVie Inc. | $67.26 |
| Consulting Fee | $7,339 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $5,000 |
| Food and Beverage | $183 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Dec 16, 2025 | Compensation for services other than consulting (speaking, faculty) NURTEC ODT · PAIN | $5,000 |
| Lundbeck LLC May 13, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $3,500 |
| Amneal Pharmaceuticals LLC Dec 4, 2025 | Consulting Fee BREKIYA · NEUROLOGY | $3,000 |
| Lundbeck LLC Apr 26, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $372 |
| Lundbeck LLC Apr 26, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $158 |
| Lundbeck LLC Jun 10, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $106 |
| Lundbeck LLC Apr 18, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $92.00 |
| Lundbeck LLC Apr 26, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $60.00 |
| Lundbeck LLC Apr 26, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $25.00 |
| Lundbeck LLC Apr 26, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $25.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $20,626 in research payments for these studies, mostly to the institutions running them.
- Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
AbbVie Inc. · Completed · NCT05216263 - A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06047444 - Preventive treatment of migraine: outcomes for patients in real-world healthcare systems (triumph)
Eli Lilly and Company - M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.